MultiCell Technologies (MCET)

http://www.multicelltech.com/

Company Information:

MultiCell Research & Development Headquarters
68 Cumberland Street, Suite 301
Woonsocket, RI 02895
401.762.0045 Office
info@multicelltech.com

MultiCell Technologies, Inc. Corporate Headquarters
68 Cumberland Street, Suite 301
Woonsocket, RI 02895
401.762.0045 Office
401.762.0098 Fax
info@multicelltech.com

CIK:  0000811779

Multicell Technologies:  Driving the next generation of medical therapies in the life-saving medicine of immune system modulation.

MultiCell is a leading-edge biopharmaceutical company committed to the development and commercialization of breakthrough therapeutics based on a portfolio of new drug candidates and patented drug development technology platforms. 

MultiCell leverages patented methods of modulating the human immune system to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza and other health threats.  Currently, the market for therapies addressing such conditions is estimated at $8 billion worldwide.

The Company's novel technologies include expertise in Toll-like receptors and T-cell targeting to modulate both the innate and adaptive immune systems, enabling the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting of the immune system. 

Management: 

http://www.multicelltech.com/management_team.html 
(note: Chang is no longer CEO, W. Gerald Newmin is. Chang is the head of partially-owned subsidiary Multicell Immunotherapeutics of San Diego and a Director of the Company.)

Board of Directors:

http://www.multicelltech.com/directors.html

Scientific Advisory Board:

http://www.multicelltech.com/advisors.html

Disease Targets & Product Pipeline

MultiCell has focused its technologies on four disease targets: multiple sclerosis (MS); type-1 diabetes; and infectious disease. The Company’s therapeutic pipeline includes MCT-125, directed at treating chronic fatigue in MS patients; MCT-175, targeting relapse-remitting MS; MCT-275, for the treatment of type-1 diabetes; and MCT-465, addressing influenza A infection. MultiCell also specializes in developing primary cell immortalization technologies to produce cell-based assay systems for use in drug discovery and for the production of therapeutic proteins.

Discovery Tools Products

http://www.multicelltech.com/discovery_products.html

Recent News: 

http://www.multicelltech.com/newsroom.html

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000811779&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:

U.S. Stock Transfer Corp.
Suite 200
Glendale, CA 91204-2991